Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ann Collins

Obstetrics & Gynecology Raleigh, NC Medical Doctor

NPI 1336120583 CMS profile 60549

4414 Lake Boone Trl, Ste 205, Raleigh, NC 27607

Open in the dashboard

General payments

$6,593

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$5

5 holdings reported · through program year 2025

Research they led as principal investigator

$693,992 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ann Collins of Raleigh, NC is reported in the CMS Open Payments database as having received $6,593 across 234 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $693,992 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $704 27
2024 General $660 33
2023 General $3,035 51
2022 General $718 38
2021 General $688 35
2020 General $363 20
2019 General $426 30
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1
2020 Ownership $1 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Collins
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Ann Collins were reported at $704. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Ann Collins Obstetrics & Gynecology median Middle half National median
2019 $426 $172 $62–$391 $163
2020 $363 $94 $36–$222 $114
2021 $688 $136 $42–$369 $132
2022 $718 $160 $50–$433 $149
2023 $3,035 $169 $56–$423 $160
2024 $660 $152 $50–$371 $164
2025 $704 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $2,094 7 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $428 22 payments
  3. AbbVie, Inc. $399 19 payments
  4. Mayne Pharma Inc. $381 15 payments
  5. Pfizer Inc. $381 25 payments
  6. Exeltis, USA Inc. $303 11 payments
  7. Astellas Pharma US Inc $226 13 payments
  8. Biogen, Inc. $166 8 payments
  9. Daiichi Sankyo Inc. $148 8 payments
  10. Avion Pharmaceuticals $142 10 payments
  11. Other $1,926 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,893 229 payments
  2. Travel and Lodging $1,676 3 payments
  3. Education $24 2 payments
Products named General payments · program years 2019–2025
  1. MYFEMBREE Hormone Therapy $2,152 10 payments
  2. PREMARIN $342 22 payments
  3. Kyleena $338 16 payments
  4. Veozah $318 16 payments
  5. ORILISSA $274 11 payments
  6. SLYND $264 8 payments
  7. ORIAHNN $197 6 payments
  8. LO LOESTRIN FE $186 12 payments
  9. MYFEMBREE Genitourinary (Sexual Health);Womens Health $178 11 payments
  10. NURTEC ODT $169 12 payments
  11. Other $3,130 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

148

Median for Obstetrics & Gynecology: 65

Drug cost

$17,945

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

27.7%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 22 $10,735
Estradiol Generic 79 $5,505
Valacyclovir Valacyclovir Hcl Brand 19 $1,125
Raloxifene Hcl Generic 28 $580

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$22,490

Medicare's payments for the services billed

Medicare patients

52

Average age 70

Services billed

877

52 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 40%
Arthritis 33%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $78
  • Astellas Pharma Global Development $50
$128 — —
SLYND
  • Exeltis, USA Inc. $35
$35 — —
Mirena
  • Bayer HealthCare Pharmaceuticals Inc. $23
$23 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $19
$19 — —
DUAVEE
  • PFIZER INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record